To discuss a potential Pradaxa bleeding lawsuit with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit website, www.FightForVictims.com.
Melville, NY (PRWEB) August 08, 2012
Andres Alonso and David Krangle, founding partners of Alonso Krangle LLP, a law firm dedicated to fighting for the rights of serious personal injury victims, report that the U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered the consolidation of all federally filed Pradaxa lawsuits in a multidistrict litigation for coordinated pretrial proceedings. According to a Transfer Order dated August 8, 2012, the Pradaxa (Dabigatran Etexilate) Products Liability Litigation (MDL No. 2385) will be presided over by U.S. District Judge David R. Herndon. [jpml.uscourts.gov/sites/jpml/files/MDL-2385-Initial_Transfer-07-12.pdf]
There is still time for victims of Pradaxa bleeding side effects to file claims in this litigation. Alonso Krangle LLP offers free Pradaxa bleeding side effects lawsuit evaluations to Pradaxa bleeding injury victims, including any Pradaxa user who has suffered:
- Cerebral Hemorrhage, or Brain Bleeds
- Gastrointestinal Bleeding, or Stomach Bleeds
- Kidney Bleeding
- Heart Attack
- Death from Serious Internal Bleeding
To discuss a potential Pradaxa bleeding lawsuit with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Pradaxa was introduced by Boehringer Ingelheim in October 2010, and touted as a superior alternative to Coumadin (warfarin) for prevention of stroke among patients with non-valvular atrial fibrillation. In December 2011, the U.S. Food & Drug Administration (FDA) released a safety communication warning patients of possible increased risk for bleeding events while taking Pradaxa. More recently, a report issued by the Institute for Safe Medication Practices reported that Pradaxa accounted for over 3000 serious adverse events in 2011, including over 500 patient deaths. [fda.gov/drugs/drugsafety/ucm282724.htm; ismp.org/quarterwatch/pdfs/2011]
Like all blood thinners, Pradaxa poses a risk of serious internal bleeding. But unlike warfarin bleeding, which can be treated via the administration of vitamin k, there is no readily available antidote for Pradaxa hemorrhaging. Among other things, lawsuits pending in the Pradaxa litigation allege Boehringer Ingelheim did not adequately inform users or the medical community about the lack of a reversal agent for Pradaxa bleeding side effects.
According to Alonso Krangle LLP, multidistrict litigations are established to reduce duplicative discovery, eliminate contradictory pretrial rulings from different judges and to serve the convenience of the witnesses, the parties and the courts when there exists a large number of claims involving similar allegations or facts. In choosing the Southern District of Illinois for the Pradaxa litigation, the JPML noted Judge Herndon’s experience as an MDL judge who has “deftly handled” another large pharmaceutical litigation, the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices & Products Liability Litigation (MDL 2100).
According to a recent report from the Madison Record, Judge Herndon was already presiding over more than a dozen Pradaxa bleeding lawsuits that had been filed in the Southern District of Illinois. In an Order dated July 25, 2012, Judge Herndon refused a Defense motion to dismiss Pradaxa claims that had argued, among other things, that the cases should be thrown out because the Pradaxa label already includes information that the drug may cause serious and sometimes fatal bleeding. Judge Herndon disagreed, noting that in addition to alleging Boehringer Ingelheim failed to warn about an increased risk of excessive or uncontrollable bleeding with Pradaxa, Plaintiffs had also alleged the company failed to warn about a lack of an antidote for Pradaxa hemorrhaging. As such, Judge Herndon found that “including a warning about the risk of serious or fatal bleeding does not justify dismissal of plaintiff’s claims.” [ilsd.uscourts.gov/opinions/ilsd_live.3.12.cv.616.2108177.0.pdf]
Alonso Krangle LLP continues to offer free legal evaluations to the victims of Pradaxa side effects. To discuss a potential claim with one of the experienced Pradaxa bleeding side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website http://www.FightForVictims.com.
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Alonso Krangle LLP
445 Broad Hollow Road
Melville, New York 11747